This information was provided by prnewswire
Send your Press Release here.
Dr. Small-Howard will elucidate GB Sciences’ Natural Products-Based Approach to Drug Discovery and is a panelist for the “Welcome Panel Session: Bringing Together Industry and Academia”.
LAS VEGAS, Dec. 11, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) announced today that Dr. Andrea Small-Howard, Chief Science Officer and GB Sciences’ Board Member, will present “Unique Methods to Identify Strong Lead Compounds” at the International Cannabinoid-Derived Pharmaceuticals Summit (“iCDP Summit”) in Boston, on December 11-12, 2018 at The Revere Hotel. The iCDP Summit is a central meeting place for leading pharma companies, research experts and clinical pioneers in the field of Cannabinoid Derived Pharmaceutical development ( http://international-cdp.com/
“Together with our academic research partners, we are defining cannabinoid-containing complex mixtures (“CCCM™”) that target specific diseases using a natural-products approach to drug discovery,” explains Dr. Small-Howard. “Our lead compounds address Parkinson’s disease by leveraging natural molecular synergies among the molecules in our proprietary CCCM™ to increase the net effectiveness of these complex API relative to single compound therapies.”
In recognition of GB Sciences’ commitment to university research partnerships, Dr. Small-Howard has also been asked to join the Welcome Panel: Bringing Together Industry and Academia. GB Sciences has assembled an exceptional international team of cannabinoid-based researchers from Chaminade University, Michigan State University, Louisiana State University AgCenter, University of Hawai’i, University of Athens in Greece, Universidad de Sevilla in Spain, Universidad de Cadiz in Spain, and the National Research Council of Canada. GB Sciences and their academic partners are working together to convert this powerful medicinal plant into more traditional medicines.
“GB Sciences is honored to be participating in this prestigious event with so many leading cannabinoid researchers, developers, and clinicians,” said John Poss, CEO and Chairman of GB Sciences, Inc.